Adial Pharmaceuticals, Inc.
|Number of Estimates|
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which is focused on the treatment of alcohol use disorder. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.
Market Cap: 17.4 Million
Primary Exchange: NASDAQ
Shares Outstanding: 10.3 Million
Float: 6.9 Million
Sector: Health Technology
Industry: Pharmaceuticals: Major
Longest drawdown: 867 trading days
From: 2019-01-15 To: 2019-12-10
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|